Fidelity Disruptive Medicine ETF Rating $24.77 +0.49 (+2.00%) Closing price 08/22/2025 03:54 PM EasternExtended Trading$24.76 -0.01 (-0.02%) As of 08/22/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Fidelity Disruptive Medicine ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.FMED Aggregate RatingModerate Buy 2.87Holdings in FMED have an aggregate rating of Moderate Buy based on 395 analyst ratings issued in the past year covering 21 companies (59.8% of the portfolio).FMED Aggregate Price Target$24.77High Prediction$24.77Average Prediction$24.77Low Prediction$24.77Holdings in FMED have an aggregate price target of $24.77 and a range of $24.77 to $24.77 covering 21 companies (59.8% of the portfolio).FMED Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy5 Buy rating(s)Moderate Buy16 Moderate Buy rating(s)Hold0 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Fidelity Disruptive Medicine ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 21 FMED Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.61%BSXBoston Scientific$106.00+0.7%4.7285 of 5 stars3.04$117.50 10.9%26Positive News5.12%ALNYAlnylam Pharmaceuticals$454.38-2.8%4.1498 of 5 stars2.85$405.33 -10.8%26News CoverageInsider Trade3.94%ARGXargenex$660.00-0.6%3.9915 of 5 stars3.10$746.81 13.2%20News CoveragePositive News3.64%VEEVVeeva Systems$291.03+3.1%3.9287 of 5 stars2.50$274.17 -5.8%24Positive NewsUpcoming Earnings3.50%DHRDanaher$211.71+3.8%4.7374 of 5 stars2.85$247.61 17.0%20News CoveragePositive News3.22%PODDInsulet$330.77+0.9%4.3491 of 5 stars2.89$332.71 0.6%18News CoveragePositive NewsAnalyst Forecast3.12%LEGNLegend Biotech$35.56+0.1%3.918 of 5 stars3.00$72.38 103.5%10News CoveragePositive News2.97%WAYWaystar$36.24+1.4%4.0833 of 5 stars3.17$44.73 23.4%12News CoveragePositive NewsInsider Trade2.92%ISRGIntuitive Surgical$476.16+1.3%4.888 of 5 stars2.60$595.95 25.2%20Trending NewsAnalyst Forecast2.87%PENPenumbra$264.67+5.3%4.7635 of 5 stars2.94$300.47 13.5%18Positive NewsInsider Trade2.80%EXASExact Sciences$47.47+1.7%4.9294 of 5 stars2.92$67.43 42.0%24Positive News2.66%MASIMasimo$148.63+3.0%4.4565 of 5 stars2.83$193.60 30.3%62.59%EWEdwards Lifesciences$81.76+0.7%4.4906 of 5 stars2.65$85.90 5.1%26Positive NewsAnalyst Revision2.52%SYKStryker$393.80+2.3%4.5302 of 5 stars2.79$430.10 9.2%19News CoveragePositive News1.88%LLYEli Lilly and Company$710.73+0.1%4.9985 of 5 stars2.65$950.17 33.7%23Trending NewsAnalyst Upgrade1.80%MRUSMerus$67.49+1.3%2.2819 of 5 stars3.09$88.50 31.1%11Positive News1.76%RMDResMed$293.48+1.8%4.4825 of 5 stars2.81$274.83 -6.4%16News CoveragePositive NewsInsider Trade1.74%ZLABZai Lab$35.04+3.1%2.4015 of 5 stars2.83$57.22 63.3%6News CoverageInsider Trade1.74%REGNRegeneron Pharmaceuticals$589.48-1.5%4.8478 of 5 stars2.81$829.65 40.7%26News CoveragePositive NewsDividend Announcement1.73%DXCMDexCom$82.26+2.0%4.8372 of 5 stars2.95$99.89 21.4%22News CoveragePositive NewsAnalyst Forecast1.71%TMOThermo Fisher Scientific$500.24+3.4%4.8547 of 5 stars2.73$593.00 18.5%22Trending NewsInsider TradeAnalyst Revision This page (NASDAQ:FMED) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fidelity Disruptive Medicine ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Fidelity Disruptive Medicine ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access